title: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation.
abstract: OBJECTIVE
  The study examined whether antiplatelet treatment with eptifibatide affected the frequency and outcome of shock among patients in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial who had acute coronary syndromes but not persistent ST-segment elevation.
  
  
  BACKGROUND
  Preliminary reports suggest a salutary effect of antiplatelet agents when shock complicates acute myocardial infarction.
  
  
  METHODS
  We analyzed the impact of antiplatelet treatment with eptifibatide on the frequency and outcome of cardiogenic shock developing after enrollment. PURSUIT was a double-blind, randomized trial that examined the efficacy of eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for < or =96 h) versus placebo among patients who had acute coronary syndromes but not persistent ST-segment elevation.
  
  
  RESULTS
  Shock developed in 2.5% of the 9,449 patients at a median (25th, 75th interquartiles) of 94.0 (38, 206) h. Death by 30 days occurred in 65.8% of shock patients. Patients who had acute myocardial infarction upon enrollment had a greater incidence of shock (2.9% vs. 2.1%, p = 0.01), developed shock earlier (40.2% <48 h vs. 20.9%, p = 0.001), and had higher 30-day mortality from shock (77.2% vs. 52.7%, p = 0.001). Randomization to eptifibatide did not affect the occurrence of shock (p = 0.71, adjusted odds ratio [OR] = 0.95, 95% confidence interval [CI] = 0.72-1.25). However, shock patients treated with eptifibatide had significantly reduced adjusted odds of 30-day death (p = 0.03, adjusted OR = 0.51, 95% CI = 0.28-0.94).
  
  
  CONCLUSIONS
  Patients with shock treated with eptifibatide had significantly reduced adjusted odds of death, suggesting a salutary effect of antiplatelet therapy on shock. This finding warrants verification in specifically designed studies.
authors.affiliation: Rabin Medical Center, Petah Tikva, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Hasdai
authors.forename: R A
authors.initials: RA
authors.lastname: Harrington
authors.forename: J S
authors.initials: JS
authors.lastname: Hochman
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: A
authors.initials: A
authors.lastname: Battler
authors.forename: J W
authors.initials: JW
authors.lastname: Box
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
authors.forename: J
authors.initials: J
authors.lastname: Deckers
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: D R
authors.initials: DR
authors.lastname: Holmes
mesh_terms: D000368:Aged; D001792:Blood Platelets / Q000378:metabolism*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000628:therapy; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012769:Shock / Q000209:etiology*; D013577:Syndrome; D013997:Time Factors
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex